Literature DB >> 25325974

Murine models in the evaluation of heparan sulfate-based anticoagulants.

David Gailani1, Qiufang Cheng, Ivan S Ivanov.   

Abstract

Evaluating anticoagulants in animal thrombosis models is a standard component of preclinical drug testing. Mice are frequently used for these initial evaluations because a variety of thrombosis models have been developed and are well characterized in this species, and the animals are relatively inexpensive to maintain. Because mice have a natural resistance to forming intravascular thrombi, vessel injury is required to induce intravascular clot formation. Several methods have been established for inducing arterial or venous thrombosis in mice. For the purpose of testing heparin-based drugs, we adapted a well-established model in which thrombus formation in the carotid artery is induced by exposing the vessel to ferric chloride. For studying anticoagulant effects on venous thrombosis, we use a model in which the inferior vena cava is ligated and the size of the resulting clots is measured. The most common adverse effect of anticoagulation therapy is bleeding. The effect of heparin-based anticoagulants can be tested in mice in a simple tail bleeding assay.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25325974      PMCID: PMC4365426          DOI: 10.1007/978-1-4939-1714-3_37

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  29 in total

1.  A tail vein bleeding time model and delayed bleeding in hemophiliac mice.

Authors:  G J Broze; Z F Yin; N Lasky
Journal:  Thromb Haemost       Date:  2001-04       Impact factor: 5.249

Review 2.  Pathogenesis of thrombosis.

Authors:  Bruce Furie
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

3.  Mechanisms underlying FeCl3-induced arterial thrombosis.

Authors:  A Eckly; B Hechler; M Freund; M Zerr; J-P Cazenave; F Lanza; P H Mangin; C Gachet
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

Review 4.  A guide to murine coagulation factor structure, function, assays, and genetic alterations.

Authors:  J J Emeis; M Jirouskova; E-M Muchitsch; A S Shet; S S Smyth; G J Johnson
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

5.  Human factor IX corrects the bleeding diathesis of mice with hemophilia B.

Authors:  S H Kung; J N Hagstrom; D Cass; S J Tai; H F Lin; D W Stafford; K A High
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

6.  A coagulation factor IX-deficient mouse model for human hemophilia B.

Authors:  H F Lin; N Maeda; O Smithies; D L Straight; D W Stafford
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

7.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

8.  Murine thrombosis models.

Authors:  Sharlene M Day; Jennifer L Reeve; Daniel D Myers; William P Fay
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

Review 9.  Murine models of vascular thrombosis (Eitzman series).

Authors:  Randal J Westrick; Mary E Winn; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06-28       Impact factor: 8.311

10.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

View more
  3 in total

1.  A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.

Authors:  Rami A Al-Horani; Elsamani I Abdelfadiel; Daniel K Afosah; Shravan Morla; Jyothi C Sistla; Bassem Mohammed; Erika J Martin; Masahiro Sakagami; Donald F Brophy; Umesh R Desai
Journal:  J Thromb Haemost       Date:  2019-09-10       Impact factor: 5.824

Review 2.  Animal models of venous thrombosis.

Authors:  Hassan Albadawi; Avery A Witting; Yash Pershad; Alex Wallace; Andrew R Fleck; Peter Hoang; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

3.  Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.

Authors:  A Y Mehta; B M Mohammed; E J Martin; D F Brophy; D Gailani; U R Desai
Journal:  J Thromb Haemost       Date:  2016-02-16       Impact factor: 5.824

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.